Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?

Bibliography

• Zhong H, Shurin MR, Han B. Optimizing dendritic cell-based immunotherapy for cancer. Expert Rev Vaccines 2007;6:333-45
   PubMed Web of Science ®Google Scholar
• Wang B, Han S, Lien L, Chang LJ. Lentiviral calnexin-modified dendritic cells promote expansion of high-avidity effector T cells with central memory phenotype. Immunology 2009;128:43-57
   PubMed Web of Science ®Google Scholar
• Higano CS, Small EJ, Schellhammer P, Nat Rev Drug Discov 2010;9:513-14
   PubMed Web of Science ®Google Scholar
• Benencia F, Courreges MC, Coukos G. Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. J Transl Med 2008;6:21
   PubMed Web of Science ®Google Scholar
• Gilboa E. DC-based cancer vaccines. J Clin Invest 2007;117:1195-203
   PubMed Web of Science ®Google Scholar
• Markovic SN, Dietz AB, Greiner CW, Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma. J Transl Med 2006;4:35
   PubMed Web of Science ®Google Scholar
• Nencioni A, Grunebach F, Schmidt S, The use of dendritic cells in cancer immunotherapy. Crit Reviews Oncol Hematol 2008;65:191-9
   PubMed Web of Science ®Google Scholar
• Smits EL, Anguille S, Cools N, Dendritic Cell-Based Cancer Gene Therapy. Hum Gene Ther 2009;20:1106-18
   PubMedGoogle Scholar
• Vulink A, Radford KJ, Melief C, Hart DN. Dendritic cells in cancer immunotherapy. Adv Cancer Res 2008;99:363-407
   PubMedGoogle Scholar
• Baratelli F, Takedatsu H, Hazra S, Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer. J Transl Med 2008:6:38
   PubMed Web of Science ®Google Scholar
• Fukushima S, Hirata S, Motomura Y, Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells. J Immunother 2009;32:219-31
   PubMed Web of Science ®Google Scholar
• He S, Wang L, Wu Y, CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo. J Exp Clin Cancer Res 2010;29:37
   PubMed Web of Science ®Google Scholar
• Jinushi M, Tahara H. Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci 2009;100:1389-96
   PubMed Web of Science ®Google Scholar
• Kikuchi T. Genetically modified dendritic cells for therapeutic immunity. Tohoku J Exp Med 2006;208:1-8
   PubMed Web of Science ®Google Scholar
• Ribas A. Genetically modified dendritic cells for cancer immunotherapy. Cur Gene Ther 2005;5:619-28
   PubMed Web of Science ®Google Scholar
• Sakai Y, Morrison BJ, Burke JD, Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res 2004;64:8022-8
   PubMed Web of Science ®Google Scholar
• Metharom P, Ellem KA, Schmidt C, Wei MQ. Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma. Hum Gene Ther 2001;12:2203-13
   PubMed Web of Science ®Google Scholar
• Pirtskhalaishvili G, Shurin GV, Gambotto A, Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice. J Immunol 2000;165:1956-64
   PubMed Web of Science ®Google Scholar
• Balkir L, Tourkova IL, Makarenkova VP, Comparative analysis of dendritic cells transduced with different anti-apoptotic molecules: sensitivity to tumor-induced apoptosis. J Gene Med 2004;6:537-44
   PubMed Web of Science ®Google Scholar
• Yurkovetsky ZR, Shurin GV, Barry DA, Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells. J Gene Med 2006;8:129-37
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Zullo SA, Ramsey J, Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J Neurosurg 2002;97:611-18
   PubMed Web of Science ®Google Scholar
• Melero I, Duarte M, Ruiz J, Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther 1999;6:1779-84
   PubMed Web of Science ®Google Scholar
• Komita H, Zhao X, Katakam AK, Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity. Cancer Gene Ther 2009;16:883-91
   PubMed Web of Science ®Google Scholar
• Satoh Y, Esche C, Gambotto A, Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol 2002;2:337-49
   PubMedGoogle Scholar
• Ojima T, Iwahashi M, Nakamura M, Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice. Int J Cancer 2007;120:585-93
   PubMed Web of Science ®Google Scholar
• Grunebach F, Kayser K, Weck MM, Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes. Cancer Gene Ther 2005;12:749-56
   PubMed Web of Science ®Google Scholar
• Geiger C, Regn S, Weinzierl A, A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma. J Transl Med 2005;3:29
   PubMed Web of Science ®Google Scholar
• Ojima T, Iwahashi M, Nakamura M, Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells. Int J Oncol 2007;31:931-9
   PubMed Web of Science ®Google Scholar
• Tourkova IL, Yurkovetsky ZR, Gambotto A, Increased function and survival of IL-15-transduced human dendritic cells are mediated by up-regulation of IL-15Ralpha and Bcl-2. J Leukoc Biol 2002;72:1037-45
   PubMed Web of Science ®Google Scholar
• Tong XM, Zheng SE, Bader A, Construction of expression vector of hTERT- hIL18 fusion gene and induction of cytotoxic T lymphocyte response against hTERT. Eur J Med Res 2008;13:7-14
   PubMed Web of Science ®Google Scholar
• Bonehill A, Tuyaerts S, Van Nuffel AM, Enhancing the T-cell Stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 2008;16:1170-80
   PubMed Web of Science ®Google Scholar
• Morrison B, Steel JC, Gregory M, Genetically modified dendritic cells in cancer immunotherapy, In shurin MR, salter RD, editors. Dendritic cells in cancer, Springer Science + Business Media, LLC, New York, NY; 2009. p. 347-64
   Google Scholar
• Heiser A, Coleman D, Dannull J, Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002;109:409-17
   PubMed Web of Science ®Google Scholar
• Morse MA, Nair SK, Mosca PJ, Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003;21:341-9
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Yang BK, Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005;174:3798-807
   PubMed Web of Science ®Google Scholar
• Mazzolini G, Alfaro C, Sangro B, Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 2005;23:999-1010
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Mirza N, Fricke I, Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12:878-87
   PubMed Web of Science ®Google Scholar
• Brennan FR, Dougan G. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. Vaccine 2005;23:3210-22
   PubMed Web of Science ®Google Scholar
• Murthy V, Moiyadi A, Sawant R, Sarin R. Clinical considerations in developing dendritic cell vaccine based immunotherapy protocols in cancer. Curr Mol Med 2009;9:725-31
   PubMed Web of Science ®Google Scholar
• Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007;220:129-50
   PubMed Web of Science ®Google Scholar
• Dannull J, Su Z, Rizzieri D, Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33
   PubMed Web of Science ®Google Scholar
• Menard C, Martin F, Apetoh L, Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 2008;57:1579-87
   PubMed Web of Science ®Google Scholar
• Woo EY, Yeh H, Chu CS, Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308
   PubMed Web of Science ®Google Scholar
• Morse MA, Hobeika AC, Osada T, Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008;112:610-18
   PubMed Web of Science ®Google Scholar
• Koike N, Pilon-Thomas S, Mule JJ. Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma. J Immunother 2008;31:402-12
   Google Scholar
• Jacobs JF, Punt CJ, Lesterhuis WJ, Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment, a phase I/II study in metastatic melanoma patients. Clin Cancer Res 2010;16:5067-78
   Google Scholar
• Shurin MR, Gabrilovich DI. Regulation of dendritic cell system by tumor. Cancer Res Ther Control 2001;11:65-78
   Google Scholar
• Shurin MR, Shurin GV, Lokshin A, Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev 2006;25:333-56
   PubMed Web of Science ®Google Scholar
• Chi CH, Wang YS, Lai YS, Chi KH. Anti-tumor effect of in vivo IL-2 and GM-CSF electrogene therapy in murine hepatoma model. Anticancer Res 2003;23:315-21
   PubMed Web of Science ®Google Scholar
• Wang YS, Tsang YW, Chi CH, Synergistic anti-tumor effect of combination radio- and immunotherapy by electro-gene therapy plus intra-tumor injection of dendritic cells. Cancer Lett 2008;266:275-85
   PubMed Web of Science ®Google Scholar
• Lizee G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res 2006;12:4794-803
   PubMed Web of Science ®Google Scholar
• Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008;371:771-83
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-96
   PubMed Web of Science ®Google Scholar
• Midgley R, Kerr D. Bevacizumab-current status and future directions. Ann Oncol 2005;16:999-1004
   PubMed Web of Science ®Google Scholar
• Tyagi P. First-line treatment with bevacizumab and paclitaxel prolongs progression-free survival in metastatic breast cancer. Clin Breast Cancer 2005;6:105-7
   Google Scholar
• Osada T, Chong G, Tansik R, The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008;57:1115-24
   PubMed Web of Science ®Google Scholar
• Huarte E, Tirapu I, Arina A, Intratumoural administration of dendritic cells: hostile environment and help by gene therapy. Expert Opin Biol Ther 2005;5:7-22
   PubMed Web of Science ®Google Scholar
• Lopez MN, Pereda C, Segal G, Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol 2009;27:945-52
   PubMed Web of Science ®Google Scholar
• Tian F, Wang L, Qin W, Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice. Cancer Lett 2008;271:333-41
   PubMed Web of Science ®Google Scholar
• Zhang M, Berndt BE, Chen JJ, Kao JY. Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy. J Immunol 2008;181:3690-7
   PubMed Web of Science ®Google Scholar
• Bronte V, Kasic T, Gri G, Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 2005;201:1257-68
   PubMed Web of Science ®Google Scholar
• De Santo C, Serafini P, Marigo I, Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci USA 2005;102:4185-90
   PubMed Web of Science ®Google Scholar
• Peng S, Kim TW, Lee JH, Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gene Ther 2005;16:584-93
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Hirano F, Kaneko K, Tamura H, Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65:1089-96
   PubMed Web of Science ®Google Scholar
• Kang TH, Lee JH, Noh KH, Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments. Int J Cancer 2007;120:1696-703
   PubMed Web of Science ®Google Scholar
• Kim TW, Lee JH, He L, Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 2005;65:309-16
   PubMed Web of Science ®Google Scholar
• Mao CP, Hung CF, Wu TC. Immunotherapeutic strategies employing RNA interference technology for the control of cancers. J Biomed Sci 2007;14:15-29
   PubMed Web of Science ®Google Scholar
• Akita H, Kogure K, Moriguchi R, Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation. J Control Release 2010;143:311-17
   PubMed Web of Science ®Google Scholar
• Liu G, Ng H, Akasaki Y, Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response. Eur J Immunol 2004;34:1680-7
   PubMed Web of Science ®Google Scholar
• Boczkowski D, Lee J, Pruitt S, Nair S. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. Cancer Gene Ther 2009;16:900-11
   PubMed Web of Science ®Google Scholar
• Woo CY, Clay TM, Lyerly HK, Role of natural killer cell function in dendritic cell-based vaccines. Expert Rev Vaccines 2006;5:55-65
   PubMed Web of Science ®Google Scholar
• Wargo J, Schumacher L, Comin-Anduix B, Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Cancer Gene Ther 2005;12:516-27
   Google Scholar
• Viaud S, Terme M, Flament C, Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One 2009, 4:e4942
   PubMed Web of Science ®Google Scholar
• Bontkes HJ, Kramer D, Ruizendaal JJ, Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells. Clin Immunol 2008;127:375-84
   PubMed Web of Science ®Google Scholar
• Morse MA, Clay TM, Hobeika AC, Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 2005;11:3017-24
   PubMed Web of Science ®Google Scholar
• Osada T, Clay T, Hobeika A, NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother 2006;55:1122-31
   PubMed Web of Science ®Google Scholar
• Hirschowitz EA, Foody T, Hidalgo GE, Yannelli JR. Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 2007;57:365-72
   Google Scholar
• Kimura H, Iizasa T, Ishikawa A, Prospective Phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients. Anticancer Res 2008;28:1229-38
   PubMed Web of Science ®Google Scholar
• Holtl L, Ramoner R, Zelle-Rieser C, Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 2005;54:663-70
   PubMed Web of Science ®Google Scholar
• Chi KH, Liu SJ, Li CP, Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 2005;28:129-35
   PubMed Web of Science ®Google Scholar
• Guo J, Zhu J, Sheng X, Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int J Cancer 2007;120:2418-25
   PubMed Web of Science ®Google Scholar
• Hirooka Y, Itoh A, Kawashima H, A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. Pancreas 2009;38:e69-74
   PubMed Web of Science ®Google Scholar
• Rains N, Cannan RJ, Chen W, Stubbs RS. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology 2001;48:347-51
   PubMed Web of Science ®Google Scholar
• Morse MA, Nair SK, Boczkowski D, The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer 2002;32:1-6
   PubMedGoogle Scholar
• Tsao H, Millman P, Linette GP, Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma. Arch Dermatol 2002;138:799-802
   Google Scholar
• Pecher G, Haring A, Kaiser L, Thiel E. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 2002;51:669-73
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Heiser A, Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003;63:2127-33
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Carlo-Stella C, Mortarini R, Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination: a Phase I trial in metastatic melanoma. Clin Cancer Res 2004;10:5381-90
   PubMed Web of Science ®Google Scholar
• Caruso DA, Orme LM, Neale AM, Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol 2004;6:236-46
   PubMed Web of Science ®Google Scholar
• Mu LJ, Kyte JA, Kvalheim G, Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 2005;93:749-56
   PubMed Web of Science ®Google Scholar
• Caruso DA, Orme LM, Amor GM, Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma. Cancer 2005;103:1280-91
   PubMed Web of Science ®Google Scholar
• Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother 2006;55:1432-42
   PubMed Web of Science ®Google Scholar
• Kyte JA, Mu L, Aamdal S, Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 2006;13:905-18
   PubMed Web of Science ®Google Scholar
• Hernando JJ, Park TW, Fischer HP, Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer. Lancet Oncol 2007;8:451-4
   PubMed Web of Science ®Google Scholar
• Kyte JA, Kvalheim G, Lislerud K, T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol Immunother 2007;56:659-75
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Comin-Anduix B, Vujanovic L, Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 2008;31:294-309
   PubMed Web of Science ®Google Scholar
• Schuurhuis DH, Verdijk P, Schreibelt G, In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res 2009;69:2927-34
   PubMed Web of Science ®Google Scholar
• Van Driessche A, Van de Velde AL, Nijs G, Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy 2009;11:653-68
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Van de Velde A, Van Driessche A, Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010;107:13824-9
   PubMed Web of Science ®Google Scholar
• Bonehill A, Van Nuffel AM, Corthals J, Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 2009;15:3366-75
   PubMed Web of Science ®Google Scholar
• Chiappori AA, Soliman H, Janssen WE, INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther 2010;10:983-91
   PubMed Web of Science ®Google Scholar